ArticleThe New England journal of medicine2017
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Article in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study.Clinical and translational science · 2022Trial
- Depletion of renal cortical collecting duct-secreted PCSK9 in early proteinuria prevents sustained nephrotic syndrome-related hypercholesterolemia.American journal of physiology. Renal physiology · 2026Article
- Chemical Modifications in Nucleic Acid Therapeutics.Methods in molecular biology (Clifton, N.J.) · 2025Review
- The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer's Disease: A Possible Target for the Disease Treatment.International journal of molecular sciences · 2024Review
- Commencement of Atorvastatin and Ezetimibe Immediately in Patients Presenting with Acute Coronary Syndrome.European cardiology · 2024Review
- The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions.Pharmacology research & perspectives · 2023Article
- Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials.Signal transduction and targeted therapy · 2022Review
- Small circular interfering RNAs (sciRNAs) as a potent therapeutic platform for gene-silencing.Nucleic acids research · 2021Article
- siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?Advanced healthcare materials · 2021Review
- RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models.The Journal of clinical investigation · 2020Article
- Safety evaluation of 2'-deoxy-2'-fluoro nucleotides in GalNAc-siRNA conjugates.Nucleic acids research · 2019Article
- An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema.RNA (New York, N.Y.) · 2019Article
- In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.BMC biology · 2019Article
- An RNA toolbox for cancer immunotherapy.Nature reviews. Drug discovery · 2018Review
- The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies.Toxicologic pathology · 2018Review
- Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs.Molecular cancer therapeutics · 2018Article
- RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo.Leukemia · 2018Article
- The chemical evolution of oligonucleotide therapies of clinical utility.Nature biotechnology · 2017Review
Corrections and comments
- Comment on
- Comment on
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28467871What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.